ACS Librexia

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstratethe Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome